In a descriptive analysis of current diabetes-related trials, Lakey et al. found that studies are not adequately addressing important issues related to disease prevention, treatment or therapeutic safety. Most of the trials had small numbers of participants, were of short duration and assessed drug therapy instead of other types of interventions or preventive strategies. Moreover, the majority of trials excluded participants at the extremes of ages.